Pfizer and Lilly’s tanezumab succeeds in second phase 3 osteoarthritis pain trial

The tanezumab 5 mg treatment arm met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients’ overall assessment